 |
|
|
| |
Safety and Efficacy of MK-5172 Plus Peginterferon Alfa-2b and Ribavirin (PR) in Cirrhotic and Noncirrhotic Treatment-Naive Patients With Hepatitis C Virus (HCV) Genotype (G)1 Infection
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Christophe Hezode,1 Savino Bruno,2 Ira Jacobson,3 Lawrence Serfaty,4 Paul Kwo,5 Amy Zhou,6 Chris Gilbert,6 Peggy Hwang,6 Janice Wahl,6 Michael Robertson,6 Niloufar Mobashery6
1Henri Mondor Hospital, University of Paris-Est, Creteil, France; 2Fatebenefratelli e Oftalmico Hospital, Milan, Italy; 3Weill Cornell Medical College, New York, NY, USA; 4Hopital Saint Antoine, APHP and INSERM UMR_938, Universite Pierre & Marie Curie, Paris, France; 5Indiana School of Medicine, Indianapolis, IN, USA; 6Merck & Co. Inc., Kenilworth, NJ, USA
EASL:
Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study - (04/11/14)
EASL: SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHy STUDY - (04/14/14)
EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS - (04/11/14)
Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients - (04/11/14)
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection - (04/11/14)
|
| |
|
|
|
|
|
